Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million

New Guidance Represents an Increase of $55 Million at the Midpoint from the Prior Range of $350 to $370 MillionStrong U.S. Demand for Amtagvi and Proleukin Drives Increased OutlookPHILADELPHIA, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. NASDAQ:IOVA, a commercial biotechnology…